The article you requested is
Novel Use of Tramadol Hydrochloride in the Treatment of Tourette’s Syndrome
J Clin Psychiatry 1997;58:174-175 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Letter to the Editor
Sir: Studies have demonstrated that symptoms of Tourette’s
syndrome can be attenuated by modulation of the opioid system.
However, the response to opioid agonists or antagonists
is often limited by side effects and the development of tolerance.
Additionally, these compounds have significant abuse potential.
The opioid tramadol hydrochloride (Ultram) has low abuse potential,
low physical dependency, and mild tolerance. It binds to
opioid receptors and also inhibits the reuptake of norepinephrine
and serotonin. We report the successful use of tramadol in the
treatment of a patient with severe Tourette’s syndrome.